{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103975","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.902892+00:00","generated_at":"2026-05-17T19:03:38.573000+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eledon reports updated Phase 1b data for tegoprubart; eGFR ~68 at 12 months, predicted 5-year graft survival >96%","bullets":["On-treatment patients (n=12) showed mean eGFR ~68 mL/min/1.73m² at 12 months; ITT population (n=15) ~63 mL/min/1.73m².","Preliminary abbreviated iBox score -4.11 (on-treatment) vs -2.98 historical CNI; predicts 5-year graft survival >96%.","No deaths, graft loss, drug-related tremor, or new-onset diabetes; six rejection episodes (18.8%), all successfully treated.","Patients who remained on tegoprubart after rejection had mean eGFR ~73 mL/min/1.73m² at 12 months; switched to tacrolimus had ~34.","Topline results from Phase 2 BESTOW trial comparing tegoprubart to tacrolimus expected in November 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103975","json":"https://secwatch.observer/filing/0000950170-25-103975.json","markdown":"https://secwatch.observer/filing/0000950170-25-103975.md","text":"https://secwatch.observer/filing/0000950170-25-103975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025103975/0000950170-25-103975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017025103975/eldn-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:03:38.573000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}